Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok
(RTTNews) - Biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR) announced Tuesday positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.
The company said it looks forward to engage with the US Food and Drug Administration (FDA) to determine the optimal path forward for Mino-Lok, which is expected to offer a much-needed alternative to the current practice of catheter removal and replacement.
European Shares Climb As Manufacturing Downturn Eases In May
FTSE 100 Modestly Higher As Factories Return To Growth
CAC 40 Gains With Focus On Upcoming ECB Meeting
DAX Climbs After PMI Data
Asian Shares Advance On US Inflation, China Manufacturing Data
Yen Falls Amid Risk Appetite
China Manufacturing Logs Fastest Growth In Nearly 2 Years
